DK1476539T3 - Streptomyces avermitilis gen dirigerende forholdet af B2:B1 avermectiner - Google Patents

Streptomyces avermitilis gen dirigerende forholdet af B2:B1 avermectiner

Info

Publication number
DK1476539T3
DK1476539T3 DK03739390T DK03739390T DK1476539T3 DK 1476539 T3 DK1476539 T3 DK 1476539T3 DK 03739390 T DK03739390 T DK 03739390T DK 03739390 T DK03739390 T DK 03739390T DK 1476539 T3 DK1476539 T3 DK 1476539T3
Authority
DK
Denmark
Prior art keywords
avermectins
streptomyces avermitilis
gene directing
ratio
avermitilis gene
Prior art date
Application number
DK03739390T
Other languages
English (en)
Inventor
Kim J Stutzman-Engwall
Claes Eric Daniel Gustafsson
Anke Krebber
Sun Ai Raillard
Jeremy Stephen Minshull
Seran Kim
Yan Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1476539T3 publication Critical patent/DK1476539T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/44Preparation of O-glycosides, e.g. glucosides
    • C12P19/60Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C12P19/623Avermectin; Milbemycin; Ivermectin; C-076
DK03739390T 2002-02-12 2003-01-31 Streptomyces avermitilis gen dirigerende forholdet af B2:B1 avermectiner DK1476539T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35622202P 2002-02-12 2002-02-12
PCT/IB2003/000348 WO2003068955A2 (en) 2002-02-12 2003-01-31 Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins

Publications (1)

Publication Number Publication Date
DK1476539T3 true DK1476539T3 (da) 2009-05-11

Family

ID=27734621

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03739390T DK1476539T3 (da) 2002-02-12 2003-01-31 Streptomyces avermitilis gen dirigerende forholdet af B2:B1 avermectiner
DK09150098.3T DK2050815T3 (da) 2002-02-12 2003-01-31 Streptomyces Avermitilis gen til regulelring af forholdet mellem B2:B1 avermectiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09150098.3T DK2050815T3 (da) 2002-02-12 2003-01-31 Streptomyces Avermitilis gen til regulelring af forholdet mellem B2:B1 avermectiner

Country Status (26)

Country Link
US (2) US7388085B2 (da)
EP (2) EP1476539B1 (da)
JP (1) JP2005517406A (da)
KR (1) KR100718378B1 (da)
CN (2) CN102392028B (da)
AR (1) AR038405A1 (da)
AT (2) ATE426659T1 (da)
AU (1) AU2003245052B2 (da)
BR (1) BRPI0307620B8 (da)
CA (1) CA2475214C (da)
CY (2) CY1110454T1 (da)
DE (1) DE60326824D1 (da)
DK (2) DK1476539T3 (da)
ES (2) ES2321827T3 (da)
HK (2) HK1074644A1 (da)
IL (3) IL162866A0 (da)
ME (1) ME00472B (da)
MX (1) MXPA04007777A (da)
PL (1) PL211693B1 (da)
PT (2) PT1476539E (da)
RS (1) RS50813B (da)
RU (1) RU2293117C2 (da)
SI (2) SI1476539T1 (da)
TW (1) TWI341330B (da)
WO (1) WO2003068955A2 (da)
ZA (1) ZA200405345B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1476539T1 (sl) 2002-02-12 2009-06-30 Pfizer Prod Inc Gen streptomyces avermitilis, ki uravnava razmerje B2:B1 avermektinov
CN102241750B (zh) * 2010-05-14 2014-05-28 中国科学院微生物研究所 一种生产阿维菌素的基因工程方法及其专用菌株
CN102093997B (zh) * 2010-12-01 2013-03-13 中国科学院上海有机化学研究所 一种改造除虫链霉菌产生多拉菌素的方法
CN109576196B (zh) * 2019-01-25 2022-01-04 北大方正集团有限公司 一种生产多拉菌素的发酵培养基及多拉菌素的生产方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4429042A (en) 1978-09-08 1984-01-31 Merck & Co., Inc. Strain of Streptomyces for producing antiparasitic compounds
IN167980B (da) 1987-01-23 1991-01-19 Pfizer
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
AU680039B2 (en) * 1993-10-05 1997-07-17 Pfizer Inc. Process and antiparasitic intermediates for doramectin
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
CN1521180A (zh) * 1998-02-13 2004-08-18 �Ʒ� 介导除虫菌素b2:b1比例的除虫链霉菌基因
US6248579B1 (en) 1998-02-13 2001-06-19 Pfizer Inc Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
US6197591B1 (en) 1998-09-14 2001-03-06 Pfizer Inc. Streptomyces avermitilis regulatory genes for increased avermectin production
KR100489856B1 (ko) * 1999-08-12 2005-05-17 화이자 프로덕츠 인코포레이티드 B2:b1 아베르멕틴의 비율을 제어하는 스트렙토마이세스아베르미틸리스 유전자
AR032130A1 (es) 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
SI1476539T1 (sl) * 2002-02-12 2009-06-30 Pfizer Prod Inc Gen streptomyces avermitilis, ki uravnava razmerje B2:B1 avermektinov

Also Published As

Publication number Publication date
RS50813B (sr) 2010-08-31
ATE426659T1 (de) 2009-04-15
CA2475214A1 (en) 2003-08-21
CN1630712A (zh) 2005-06-22
AU2003245052A1 (en) 2003-09-04
BRPI0307620B8 (pt) 2016-09-13
US20030166165A1 (en) 2003-09-04
IL192371A0 (en) 2008-12-29
DE60326824D1 (de) 2009-05-07
KR100718378B1 (ko) 2007-05-14
CY1110454T1 (el) 2015-04-29
HK1168383A1 (en) 2012-12-28
ZA200405345B (en) 2005-06-14
PT2050815E (pt) 2012-01-02
ES2321827T3 (es) 2009-06-12
CA2475214C (en) 2012-07-31
CN102392028A (zh) 2012-03-28
BRPI0307620B1 (pt) 2015-08-11
WO2003068955A3 (en) 2003-11-13
EP1476539A2 (en) 2004-11-17
DK2050815T3 (da) 2011-12-12
SI1476539T1 (sl) 2009-06-30
AU2003245052B2 (en) 2008-07-31
US20090017508A1 (en) 2009-01-15
RS70004A (en) 2006-10-27
EP2050815A1 (en) 2009-04-22
US7388085B2 (en) 2008-06-17
WO2003068955A2 (en) 2003-08-21
CY1112491T1 (el) 2015-12-09
RU2293117C2 (ru) 2007-02-10
PL371320A1 (en) 2005-06-13
SI2050815T1 (sl) 2012-01-31
ES2373629T3 (es) 2012-02-07
ATE530645T1 (de) 2011-11-15
HK1074644A1 (en) 2005-11-18
US8008078B2 (en) 2011-08-30
EP2050815B1 (en) 2011-10-26
IL162866A0 (en) 2005-11-20
CN102392028B (zh) 2013-08-14
IL192371A (en) 2010-11-30
TWI341330B (en) 2011-05-01
PL211693B1 (pl) 2012-06-29
TW200303918A (en) 2003-09-16
MXPA04007777A (es) 2004-10-15
RU2004124521A (ru) 2005-04-10
KR20040081199A (ko) 2004-09-20
EP1476539B1 (en) 2009-03-25
IL162866A (en) 2009-11-18
BR0307620A (pt) 2004-12-07
AR038405A1 (es) 2005-01-12
CN1630712B (zh) 2011-09-28
JP2005517406A (ja) 2005-06-16
ME00472B (me) 2011-10-10
PT1476539E (pt) 2009-04-09

Similar Documents

Publication Publication Date Title
EE200300575A (et) Asitromütsiini kristalsed vormid
DE60319962D1 (de) Multimodus-synchronisation
DE60307503D1 (de) Antivirale nukleosidderivate
AU2003241621A1 (en) Oligonucleotides having modified nucleoside units
DK2377931T3 (da) Varianter af glycosidhydrolase
DK1670561T3 (da) Tyndtlags fordamper
FI20021262A (fi) Sokerien kiteytys
DE602004027322D1 (de) Übertragungssynchronisierung
HK1168383A1 (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
IL161560A0 (en) Anthelmintic compositions containing milbemycin derivatives
NO20020665D0 (no) Streptomyces Avermitilis gen som bestemmer forholdet til B2:B1 avermectiner
ZA200507475B (en) Derivatives of azithromycin
DK1200606T3 (da) Streptomyces avermitilis genet, der styrer ratioen af B2:B1 avermectiner
FR2862995B1 (fr) Poutre souple autocontrainte et portiques souples parasismiques
AU2003279392A1 (en) Pharmaceutical compositions of azithromycin
DK1200605T3 (da) Streptomyces avermitilis gen, der dirigerer forholdet imellem B2:B1 avermectiner
AU2003253701A1 (en) 11-c-substituted derivatives of clarithromycin
AU2003300544A1 (en) -modified nucleoside derivatives for treating flaviviridae infections
FI20031748A0 (fi) Nukleiinihappoalukkeita ja menetelmiä, joissa niitä käytetään
CY2003001I2 (el) Τοπικες συνθεσεις μακρολιδιων
AU2003267572A1 (en) Antibiotic derivatives of erythromycin
AU2003217311A1 (en) Base-labeled nucleosides and nucleotides
IL150086A0 (en) Compositions for selective targeting of antibiotics
AU2002338932A1 (en) Antiviral nucleoside derivatives